Evolus Inc logo

EOLS

Evolus Inc

$10.24

Earnings Summary

Revenue
$0.04Mn
Net Profits
$-0.02Mn
Net Profit Margins
-63.16%

Highlights

Revenue:

Evolus Inc’s revenue fell -99.86% since last year same period to $0.04Mn in the Q2 2022. On a quarterly growth basis, Evolus Inc has generated -99.89% fall in its revenue since last 3-months.

Net Profits:

Evolus Inc’s net profit jumped 99.85% since last year same period to $-0.02Mn in the Q2 2022. On a quarterly growth basis, Evolus Inc has generated 99.87% jump in its net profits since last 3-months.

Net Profit Margins:

Evolus Inc’s net profit margin fell -5.65% since last year same period to -63.16% in the Q2 2022. On a quarterly growth basis, Evolus Inc has generated -23.09% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Evolus Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.25
EPS Estimate Current Year
-0.25

Highlights

EPS Estimate Current Quarter:

Evolus Inc’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a -4.17% fall from last quarter’s estimates.

EPS Estimate Current Year:

Evolus Inc’s earning per share (EPS) estimates for the current year stand at -0.25.

Key Ratios

Key ratios of the Evolus Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.28
Return on Assets (ROA)
-0.18
Return on Equity (ROE)
-1.03
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Evolus Inc’s earning per share (EPS) fell -47.37% since last year same period to -0.28 in the Q2 2022. This indicates that the Evolus Inc has generated -47.37% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Evolus Inc’s return on assets (ROA) stands at -0.18.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Evolus Inc’s return on equity (ROE) stands at -1.03.

Dividend Per Share (DPS):

Evolus Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.33
-0.22
33.33%
2022-08-02
-0.24
-0.28
-16.67%

Company Information

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.

Organisation
Evolus Inc
Headquarters
Newport Beach, California, United States
Employees
119
Industry
Health Technology
CEO
David Moatazedi